KEGG   PATHWAY: mcc05224
Entry
mcc05224                    Pathway                                
Name
Breast cancer - Macaca mulatta (rhesus monkey)
Description
Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.
Class
Human Diseases; Cancer: specific types
Pathway map
mcc05224  Breast cancer
mcc05224

Organism
Macaca mulatta (rhesus monkey) [GN:mcc]
Gene
613025  ESR1; estrogen receptor isoform X1 [KO:K08550]
574110  ESR2; estrogen receptor beta [KO:K08551]
718524  NCOA1; nuclear receptor coactivator 1 isoform X1 [KO:K09101] [EC:2.3.1.48]
705431  NCOA3; nuclear receptor coactivator 3 isoform X1 [KO:K11256] [EC:2.3.1.48]
702077  FOS; proto-oncogene c-Fos [KO:K04379]
716452  JUN; transcription factor AP-1 [KO:K04448]
702710  SP1; transcription factor Sp1 [KO:K04684]
574320  CCND1; G1/S-specific cyclin-D1 [KO:K04503]
694626  MYC; myc proto-oncogene protein [KO:K04377]
613024  PGR; progesterone receptor isoform 1 [KO:K08556]
709009  WNT1; proto-oncogene Wnt-1 [KO:K03209]
707864  WNT4; protein Wnt-4 isoform X1 [KO:K00408]
699955  TNFSF11; tumor necrosis factor ligand superfamily member 11 [KO:K05473]
697573  ERBB2; receptor tyrosine-protein kinase erbB-2 isoform X1 [KO:K05083] [EC:2.7.10.1]
705970  FGF1; fibroblast growth factor 1 [KO:K18496]
574136  FGF2; fibroblast growth factor 2 [KO:K18497]
710739  FGF6; fibroblast growth factor 6 [KO:K04358]
574345  FGF7; fibroblast growth factor 7 precursor [KO:K04358]
701584  FGF10; fibroblast growth factor 10 precursor [KO:K04358]
705612  FGF16; fibroblast growth factor 16 [KO:K04358]
702727  FGF22; fibroblast growth factor 22 precursor [KO:K04358]
701847  FGF20; fibroblast growth factor 20 [KO:K04358]
708918  FGF3; fibroblast growth factor 3 precursor [KO:K04358]
709016  FGF4; fibroblast growth factor 4 [KO:K04358]
706659  FGF17; fibroblast growth factor 17 precursor [KO:K04358]
721324  FGF9; fibroblast growth factor 9 [KO:K04358]
695896  FGF5; fibroblast growth factor 5 isoform X1 [KO:K04358]
702072  FGF18; fibroblast growth factor 18 [KO:K04358]
722394  FGF8; fibroblast growth factor 8 [KO:K04358]
709109  FGF19; fibroblast growth factor 19 [KO:K22603]
718288  FGF21; fibroblast growth factor 21 [KO:K22429]
710643  FGF23; fibroblast growth factor 23 precursor [KO:K22428]
700126  FGFR1; fibroblast growth factor receptor 1 precursor [KO:K04362] [EC:2.7.10.1]
698444  IGF1; insulin-like growth factor I precursor [KO:K05459]
708227  IGF1R; insulin-like growth factor 1 receptor precursor [KO:K05087] [EC:2.7.10.1]
698619  EGF; pro-epidermal growth factor isoform X2 [KO:K04357]
613027  EGFR; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
696759  KIT; mast/stem cell growth factor receptor Kit precursor [KO:K05091] [EC:2.7.10.1]
718982  SHC1; SHC-transforming protein 1 [KO:K06279]
721021  SHC2; SHC-transforming protein 2 [KO:K17447]
574275  SHC3; SHC-transforming protein 3 [KO:K17448]
714611  SHC4; SHC-transforming protein 4 [KO:K17449]
702041  GRB2; growth factor receptor-bound protein 2 [KO:K04364]
713777  SOS1; son of sevenless homolog 1 isoform X1 [KO:K03099]
705601  SOS2; son of sevenless homolog 2 [KO:K03099]
698830  HRAS; GTPase HRas [KO:K02833]
707977  KRAS; GTPase KRas [KO:K07827]
709089  NRAS; GTPase NRas [KO:K07828]
707169  ARAF; serine/threonine-protein kinase A-Raf [KO:K08845] [EC:2.7.11.1]
693554  BRAF; serine/threonine-protein kinase B-raf isoform X1 [KO:K04365] [EC:2.7.11.1]
694725  RAF1; RAF proto-oncogene serine/threonine-protein kinase [KO:K04366] [EC:2.7.11.1]
710415  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
721821  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 isoform X1 [KO:K04369] [EC:2.7.12.2]
708938  MAPK3; mitogen-activated protein kinase 3 isoform X1 [KO:K04371] [EC:2.7.11.24]
698569  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
716098  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
709959  PIK3CA; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
710552  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
707310  PIK3R3; phosphatidylinositol 3-kinase regulatory subunit gamma [KO:K02649]
719367  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
698996  PIK3R1; phosphatidylinositol 3-kinase regulatory subunit alpha [KO:K02649]
705121  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
714717  AKT3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
697747  AKT1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
700591  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
106992736  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
721731  RPS6KB2; ribosomal protein S6 kinase beta-2 isoform X2 [KO:K04688] [EC:2.7.11.1]
711979  RPS6KB1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
718580  JAG1; protein jagged-1 [KO:K06052]
708991  JAG2; protein jagged-2 isoform X1 [KO:K21635]
697453  DLL3; LOW QUALITY PROTEIN: delta-like protein 3 [KO:K06051]
704898  DLL4; delta-like protein 4 [KO:K06051]
714731  DLL1; delta-like protein 1 [KO:K06051]
709947  NOTCH1; neurogenic locus notch homolog protein 1 [KO:K02599]
713798  NOTCH2; neurogenic locus notch homolog protein 2 precursor [KO:K20994]
719119  NOTCH3; neurogenic locus notch homolog protein 3 [KO:K20995]
717323  NOTCH4; neurogenic locus notch homolog protein 4 isoform X1 [KO:K20996]
707140  HES1; transcription factor HES-1 [KO:K06054]
694929  HES5; transcription factor HES-5 isoform X1 [KO:K06055]
712988  HEY2; hairy/enhancer-of-split related with YRPW motif protein 2 [KO:K09091]
716117  HEYL; hairy/enhancer-of-split related with YRPW motif-like protein [KO:K09091]
699385  HEY1; hairy/enhancer-of-split related with YRPW motif protein 1 isoform X1 [KO:K09091]
716412  FLT4; vascular endothelial growth factor receptor 3 isoform X1 [KO:K05097] [EC:2.7.10.1]
719199  CDKN1A; cyclin-dependent kinase inhibitor 1 [KO:K06625]
714689  nuclear factor NF-kappa-B p100 subunit isoform X1 [KO:K04469]
114669860  NFKB2; LOW QUALITY PROTEIN: nuclear factor NF-kappa-B p100 subunit [KO:K04469]
704991  WNT2; protein Wnt-2 precursor [KO:K00182]
705773  WNT2B; protein Wnt-2b [KO:K00182]
716909  WNT3; proto-oncogene Wnt-3 [KO:K00312]
696200  WNT3A; protein Wnt-3a [KO:K00312]
721685  WNT5B; protein Wnt-5b [KO:K00444]
705692  WNT5A; protein Wnt-5a isoform X2 [KO:K00444]
700573  WNT6; protein Wnt-6 isoform X1 [KO:K00445]
713864  WNT7B; protein Wnt-7b isoform X2 [KO:K00572]
693419  WNT7A; protein Wnt-7a [KO:K00572]
710242  WNT8B; protein Wnt-8b [KO:K00714]
713764  WNT8A; protein Wnt-8a [KO:K00714]
716877  WNT9B; protein Wnt-9b [KO:K01064]
696326  WNT9A; protein Wnt-9a isoform X1 [KO:K01064]
700692  WNT10A; protein Wnt-10a [KO:K01357]
708906  WNT10B; protein Wnt-10b precursor [KO:K01357]
696845  WNT11; protein Wnt-11 isoform X2 [KO:K01384]
694069  WNT16; protein Wnt-16 isoform X1 [KO:K01558]
703942  FZD1; frizzled-1 [KO:K02432]
703064  FZD7; frizzled-7 [KO:K02432]
712381  FZD2; frizzled-2 [KO:K02235]
713839  FZD3; frizzled-3 precursor [KO:K02329]
704754  FZD4; frizzled-4 precursor [KO:K02354]
708368  FZD8; frizzled-8 [KO:K02375]
710796  FZD5; frizzled-5 [KO:K02375]
694625  FZD6; frizzled-6 precursor [KO:K02376]
717812  FZD10; frizzled-10 [KO:K02842]
716392  FZD9; frizzled-9 [KO:K02842]
721605  LRP5; low-density lipoprotein receptor-related protein 5 isoform X1 [KO:K03068]
695843  LRP6; low-density lipoprotein receptor-related protein 6 precursor [KO:K03068]
714381  DVL2; segment polarity protein dishevelled homolog DVL-2 [KO:K02353]
100423838  DVL3; segment polarity protein dishevelled homolog DVL-3 isoform X1 [KO:K02353]
705864  DVL1; segment polarity protein dishevelled homolog DVL-1 isoform X1 [KO:K02353]
705609  FRAT1; proto-oncogene FRAT1 [KO:K03069]
705730  FRAT2; GSK-3-binding protein FRAT2 [KO:K03096]
713114  GSK3B; glycogen synthase kinase-3 beta isoform X1 [KO:K03083] [EC:2.7.11.26]
100424087  AXIN1; axin-1 isoform X1 [KO:K02157]
718566  AXIN2; axin-2 isoform X1 [KO:K04385]
707345  APC2; adenomatous polyposis coli protein 2 isoform X1 [KO:K02085]
693443  APC; adenomatous polyposis coli protein isoform X1 [KO:K02085]
574265  CTNNB1; catenin beta-1 [KO:K02105]
710775  CSNK1A1; casein kinase I isoform alpha [KO:K08957] [EC:2.7.11.1]
695190  CSNK1A1L; casein kinase I isoform alpha-like [KO:K08957] [EC:2.7.11.1]
710234  TCF7; transcription factor 7 isoform X3 [KO:K02620]
694560  TCF7L1; transcription factor 7-like 1 isoform X2 [KO:K04490]
701759  TCF7L2; transcription factor 7-like 2 isoform X9 [KO:K04491]
695776  LEF1; lymphoid enhancer-binding factor 1 isoform X3 [KO:K04492]
716170  TP53; cellular tumor antigen p53 [KO:K04451]
697835  GADD45G; growth arrest and DNA damage-inducible protein GADD45 gamma [KO:K04402]
701054  GADD45A; growth arrest and DNA damage-inducible protein GADD45 alpha [KO:K04402]
711257  GADD45B; growth arrest and DNA damage-inducible protein GADD45 beta [KO:K04402]
718948  BAX; apoptosis regulator BAX [KO:K02159]
706534  BAK1; bcl-2 homologous antagonist/killer [KO:K14021]
114675515  bcl-2 homologous antagonist/killer-like [KO:K14021]
713813  DDB2; DNA damage-binding protein 2 [KO:K10140]
114672263  LOW QUALITY PROTEIN: DNA damage-binding protein 2-like [KO:K10140]
705713  POLK; DNA polymerase kappa isoform X1 [KO:K03511] [EC:2.7.7.7]
715650  CDK4; cyclin-dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
701822  CDK6; cyclin-dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
704871  RB1; retinoblastoma-associated protein [KO:K06618]
714126  E2F1; transcription factor E2F1 [KO:K17454]
710200  E2F2; transcription factor E2F2 [KO:K09389]
713904  E2F3; transcription factor E2F3 isoform X1 [KO:K06620]
712634  BRCA1; breast cancer type 1 susceptibility protein homolog [KO:K10605] [EC:2.3.2.27]
721981  BRCA2; LOW QUALITY PROTEIN: breast cancer type 2 susceptibility protein [KO:K08775]
Compound
C00410  Progesterone
C00951  Estradiol-17beta
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
PMID:24649067
  Authors
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  Title
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  Journal
Biomed Rep 2:41-52 (2014)
DOI:10.3892/br.2013.187
Reference
PMID:27390604
  Authors
Dai X, Xiang L, Li T, Bai Z
  Title
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
  Journal
J Cancer 7:1281-94 (2016)
DOI:10.7150/jca.13141
Reference
PMID:20436504
  Authors
Schnitt SJ
  Title
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
  Journal
Mod Pathol 23 Suppl 2:S60-4 (2010)
DOI:10.1038/modpathol.2010.33
Reference
PMID:23000897
  Authors
  Title
Comprehensive molecular portraits of human breast tumours.
  Journal
Nature 490:61-70 (2012)
DOI:10.1038/nature11412
Reference
PMID:22178455
  Authors
Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A
  Title
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
  Journal
Cancer Treat Rev 38:698-707 (2012)
DOI:10.1016/j.ctrv.2011.11.005
Reference
  Authors
Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.
  Title
Targeting androgen/estrogen receptors crosstalk in cancer
  Journal
Trends Cancer 2:35-48 (2016)
DOI:10.1016/j.trecan.2015.12.001
Reference
  Authors
Sharp A, Harper-Wynne C.
  Title
Treatment of advanced breast cancer (ABC): the expanding landscape of targeted therapies
  Journal
J Cancer Biol Res 2:1036 (2014)
Reference
PMID:24596345
  Authors
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S
  Title
Genetic and epigenetic aspects of breast cancer progression and therapy.
  Journal
Anticancer Res 34:1071-7 (2014)
Reference
PMID:23988612
  Authors
Mohamed A, Krajewski K, Cakar B, Ma CX
  Title
Targeted therapy for breast cancer.
  Journal
Am J Pathol 183:1096-112 (2013)
DOI:10.1016/j.ajpath.2013.07.005
Reference
PMID:22722193
  Authors
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
  Title
Whole-genome analysis informs breast cancer response to aromatase inhibition.
  Journal
Nature 486:353-60 (2012)
DOI:10.1038/nature11143
Reference
PMID:25907219
  Authors
Ma CX, Reinert T, Chmielewska I, Ellis MJ
  Title
Mechanisms of aromatase inhibitor resistance.
  Journal
Nat Rev Cancer 15:261-75 (2015)
DOI:10.1038/nrc3920
Reference
PMID:16113099
  Authors
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL
  Title
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
  Journal
Endocr Relat Cancer 12 Suppl 1:S47-59 (2005)
DOI:10.1677/erc.1.00993
Reference
PMID:24111892
  Authors
Dasgupta S, Lonard DM, O'Malley BW
  Title
Nuclear receptor coactivators: master regulators of human health and disease.
  Journal
Annu Rev Med 65:279-92 (2014)
DOI:10.1146/annurev-med-051812-145316
Reference
PMID:23702927
  Authors
Brisken C
  Title
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
  Journal
Nat Rev Cancer 13:385-96 (2013)
DOI:10.1038/nrc3518
Reference
PMID:20087430
  Authors
Scarpin KM, Graham JD, Mote PA, Clarke CL
  Title
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.
  Journal
Nucl Recept Signal 7:e009 (2009)
DOI:10.1621/nrs.07009
Reference
PMID:24291072
  Authors
Knutson TP, Lange CA
  Title
Tracking progesterone receptor-mediated actions in breast cancer.
  Journal
Pharmacol Ther 142:114-25 (2014)
DOI:10.1016/j.pharmthera.2013.11.010
Reference
PMID:25544707
  Authors
Dittrich A, Gautrey H, Browell D, Tyson-Capper A
  Title
The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
  Journal
J Mammary Gland Biol Neoplasia 19:253-70 (2014)
DOI:10.1007/s10911-014-9329-5
Reference
PMID:21965336
  Authors
Higgins MJ, Baselga J
  Title
Targeted therapies for breast cancer.
  Journal
J Clin Invest 121:3797-803 (2011)
DOI:10.1172/JCI57152
Reference
PMID:26028978
  Authors
Mukohara T
  Title
PI3K mutations in breast cancer: prognostic and therapeutic implications.
  Journal
Breast Cancer (Dove Med Press) 7:111-23 (2015)
DOI:10.2147/BCTT.S60696
Reference
PMID:19088017
  Authors
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA
  Title
Triple-negative breast cancer: risk factors to potential targets.
  Journal
Clin Cancer Res 14:8010-8 (2008)
DOI:10.1158/1078-0432.CCR-08-1208
Reference
PMID:21898546
  Authors
King TD, Suto MJ, Li Y
  Title
The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.
  Journal
J Cell Biochem 113:13-8 (2012)
DOI:10.1002/jcb.23350
Reference
PMID:11737884
  Authors
Brown AM
  Title
Wnt signaling in breast cancer: have we come full circle?
  Journal
Breast Cancer Res 3:351-5 (2001)
DOI:10.1186/bcr321
Reference
PMID:21076461
  Authors
Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS
  Title
beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
  Journal
Mod Pathol 24:209-31 (2011)
DOI:10.1038/modpathol.2010.205
Reference
PMID:20971825
  Authors
Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS
  Title
Notch signaling pathway as a therapeutic target in breast cancer.
  Journal
Mol Cancer Ther 10:9-15 (2011)
DOI:10.1158/1535-7163.MCT-10-0677
Reference
PMID:26968398
  Authors
Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS
  Title
Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
  Journal
Breast Cancer Res Treat 156:211-26 (2016)
DOI:10.1007/s10549-016-3746-7
Reference
PMID:26040571
  Authors
Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N
  Title
Therapeutic targets of triple-negative breast cancer: a review.
  Journal
Br J Pharmacol 172:4228-37 (2015)
DOI:10.1111/bph.13211
Reference
PMID:23196196
  Authors
Karamboulas C, Ailles L
  Title
Developmental signaling pathways in cancer stem cells of solid tumors.
  Journal
Biochim Biophys Acta 1830:2481-95 (2013)
DOI:10.1016/j.bbagen.2012.11.008
Reference
PMID:23881035
  Authors
Ignatiadis M, Sotiriou C
  Title
Luminal breast cancer: from biology to treatment.
  Journal
Nat Rev Clin Oncol 10:494-506 (2013)
DOI:10.1038/nrclinonc.2013.124
Reference
PMID:25013431
  Authors
Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH
  Title
Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.
  Journal
J Breast Cancer 17:113-20 (2014)
DOI:10.4048/jbc.2014.17.2.113
Reference
PMID:11879567
  Authors
Gasco M, Shami S, Crook T
  Title
The p53 pathway in breast cancer.
  Journal
Breast Cancer Res 4:70-6 (2002)
DOI:10.1186/bcr426
Reference
PMID:15343273
  Authors
Narod SA, Foulkes WD
  Title
BRCA1 and BRCA2: 1994 and beyond.
  Journal
Nat Rev Cancer 4:665-76 (2004)
DOI:10.1038/nrc1431
Related
pathway
mcc03440  Homologous recombination
mcc04010  MAPK signaling pathway
mcc04110  Cell cycle
mcc04115  p53 signaling pathway
mcc04151  PI3K-Akt signaling pathway
mcc04310  Wnt signaling pathway
mcc04330  Notch signaling pathway
mcc04915  Estrogen signaling pathway
KO pathway
ko05224   
LinkDB

DBGET integrated database retrieval system